article Open AccessTop 1% cited

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

The Lancet Oncology · 2015 · Vol. 16(8) · pp. 908–918

Antoni Ribas✉(University of California, Los Angeles)Igor Puzanov(Vanderbilt-Ingram Cancer Center)Reinhard Dummer(University of Zurich)Dirk Schadendorf(Essen University Hospital)Omid Hamid(Angeles Clinic and Research Institute)Caroline Robert(Institut Gustave Roussy)F. Stephen Hodi(Dana-Farber Cancer Institute)Jacob Schachter(Sheba Medical Center)Anna C. Pavlick(New York University)Karl D. Lewis(University of Colorado Denver)Lee D. Cranmer(University of Arizona)Christian U. Blank(The Netherlands Cancer Institute)Steven O’Day(Beverly Hills Cancer Center)Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")April K.S. Salama(Duke Cancer Institute)Kim Margolin(University of Washington)Carmen Loquai(Johannes Gutenberg University Mainz)Thomas Eigentler(Universitätsklinikum Tübingen)Tara C. Gangadhar(University of Pennsylvania)Matteo S. Carlino(Melanoma Institute Australia)Sanjiv S. Agarwala(Temple University)Stergios J. Moschos(University of North Carolina at Chapel Hill)Jeffrey A. Sosman(Vanderbilt University)Simone M. Goldinger(University of Zurich)Ronnie Shapira‐Frommer(Sheba Medical Center)René González(University of Colorado Denver)John M. Kirkwood(University of Pittsburgh)Jedd D. Wolchok(Memorial Sloan Kettering Cancer Center)Alexander M.M. Eggermont(Université Paris-Sud)Xiaoyun Li(Merck & Co., Inc., Rahway, NJ, USA (United States))Wei Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States))Adriane M Zernhelt(Merck & Co., Inc., Rahway, NJ, USA (United States))Joy Lis(Merck & Co., Inc., Rahway, NJ, USA (United States))Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))Sunyu Kang(Merck & Co., Inc., Rahway, NJ, USA (United States))Adil Daud(University of California, San Francisco)

View via DOI Full-text PDF

Cancer Immunotherapy and Biomarkers CAR-T cell therapy research Melanoma and MAPK PathwaysMedicineIpilimumabPembrolizumabInternal medicineCarboplatinClinical endpointAdverse effectDacarbazineOncologyTemozolomide

MeSH terms

IpilimumabAdolescentAdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMelanomaMiddle AgedSkin NeoplasmsTime Factors

Citations

1,554

FWCI

103.03

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence